Nurix Therapeutics, Inc. NRIX
16.14 USD +0.84 (+5.49%)
At closeNov 10, 2026, 6:40 AM EST
16.15 +0.01 +0.06%
Pre-market · Nov 10, 6:40 AM ET
15.27 Day range 16.63
12.01 52-week range 28.23
- YTD
- -14.92%
- 1 year
- +31.76%
News
globenewswire.com Nurix Therapeutics to Present New and Updated Data from Ongoing Phase 1a/1b Trial of Bexobrutideg (NX-5948) in Relapsed/Refractory CLL/SLL at the 68th ASH Annual Meeting and Exposition BRISBANE, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Curis (NASDAQ:CRIS) shares moved upwards by 61.8% to $1.16 during Wednesday's regular session. The market value of their outstanding shares is at $1.7 million. Lyell Immunopharma…
benzinga.com Crude Oil Down 5%; Uber Shares Jump After Q3 Results U.S. stocks rallied, led by the Dow and Nasdaq; Uber surged on revenue growth despite an earnings miss. Oil fell, while gold and silver climbed.
benzinga.com Wells Fargo Maintains Equal-Weight on Nurix Therapeutics, Lowers Price Target to $20 Wells Fargo analyst Derek Archila maintains Nurix Therapeutics (NASDAQ:NRIX) with a Equal-Weight and lowers the price target from $25 to $20.
benzinga.com Dow Jumps Over 1,100 Points; McDonald’s Shares Gain Following Upbeat Earnings U.S. stocks rallied, led by a 1,100-point Dow gain. McDonald’s rose on strong earnings; oil fell 3%, while gold and silver climbed.
benzinga.com Amdocs Posts Downbeat Q4 Earnings, Joins Skyworks Solutions, Tesla And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session U.S. stock futures rose, while Amdocs plunged 39% after missing Q4 estimates and issuing weak FY27 guidance; several other stocks also fell premarket.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers Curis (NASDAQ:CRIS) stock moved upwards by 83.5% to $1.31 during Wednesday's pre-market session. The company's market cap stands at $1.7 million. SCWorx (NASDAQ:WORX) stock increased by…
benzinga.com Why Limbach Holdings Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket Limbach surged 14.7% after beating Q3 estimates and raising FY26 sales guidance; Curis gained 69.5%, while Cenntro plunged 46.5%.
benzinga.com Nurix Therapeutics Announces That Sanofi Notified Co. Of Its Decision To Discontinue The Phase 1 First-In-Human Clinical Trial Of SAR448272, And To Terminate The SAR448272 Program Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines, today announced that Sanofi notified Nurix of its decision to…- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers Nordicus Partners (NASDAQ:NORD) stock increased by 10.8% to $4.5 during Tuesday's after-market session. The market value of their outstanding shares is at $71.5 million. Gelteq (NASDAQ:GELS)…
globenewswire.com Nurix Therapeutics Announces Sanofi's Decision to Discontinue Development of STAT6 Degrader SAR448272 BRISBANE, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines, today…
benzinga.com SpaceX To Rally Around 85%? Here Are 10 Top Analyst Forecasts For Friday Wall Street analysts raised targets for MSTR, FOXA, NRIX, ZETA and TWLO, while cutting targets for CAMT and DVN.
benzinga.com HC Wainwright & Co. Maintains Buy on Nurix Therapeutics, Raises Price Target to $36 HC Wainwright & Co. analyst Robert Burns maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and raises the price target from $34 to $36.
benzinga.com RBC Capital Maintains Outperform on Nurix Therapeutics, Lowers Price Target to $35 RBC Capital analyst Brian Abrahams maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and lowers the price target from $36 to $35.- benzinga.com Oppenheimer Maintains Outperform on Nurix Therapeutics, Raises Price Target to $32 Oppenheimer analyst Kostas Biliouris maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and raises the price target from $28 to $32.
- benzinga.com Truist Securities Maintains Buy on Nurix Therapeutics, Lowers Price Target to $33 Truist Securities analyst Gregory Renza maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and lowers the price target from $34 to $33.
- benzinga.com Baird Maintains Outperform on Nurix Therapeutics, Raises Price Target to $36 Baird analyst Joel Beatty maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and raises the price target from $33 to $36.
- benzinga.com CORRECTION: Nurix Therapeutics Q3 EPS $4.73 Beats $3.98 Estimate, Sales $673.064M Beat $411.481M Estimate Nurix Therapeutics (NASDAQ:NRIX) reported quarterly earnings of $4.73 per share which beat the analyst consensus estimate of $3.98 by 18.84 percent. This is a 559.22 percent increase over losses of…
benzinga.com 10 Health Care Stocks With Whale Alerts In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…